MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
Hagens Berman, a national securities litigation law firm, has launched an investigation into Madrigal Pharmaceuticals (NASDAQ: MDGL) following whistleblower allegations of clinical data integrity concerns regarding its drug, Rezdiffra (resmetirom). The inquiry stems from a whistleblower complaint by a former Senior Vice President alleging suppressed adverse liver-injury data, discrepancies in efficacy results, and improper board oversight. This news led to a significant drop in Madrigal's stock price, and the firm is now seeking information from investors who suffered losses.
Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
Sonic Incytes Medical Corp. has partnered with Madrigal Pharmaceuticals, Inc. in a multi-year agreement to improve non-invasive liver assessment for patients with or at risk for MASH. The collaboration aims to expand the use of point-of-care non-invasive tests, such as Sonic Incytes' Velacur ONE® platform, to facilitate earlier identification and management of MASH, a significantly underdiagnosed liver disease. This initiative will focus on integrating advanced diagnostic tools into clinical practice across various medical specialties.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted inducement awards, including stock options and restricted stock units, to 23 new non-executive employees on November 1 and November 14, 2026. These awards, totaling 842 stock options at $430.36 and 8,296 RSUs, were approved under Nasdaq Listing Rule 5635(c)(4) to incentivize new hires. The awards vest over several years, promoting employee retention but also potentially diluting existing shareholder value over time.
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for potential securities law violations after a former employee filed a whistleblower lawsuit. The lawsuit alleges retaliation under the Sarbanes-Oxley Act, claiming the employee raised concerns about company data and reporting practices. Following the news of the lawsuit, Madrigal's stock price dropped by over 8%.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity inducement awards to 23 new non-executive employees on November 1 and November 14, 2026, under its 2025 Inducement Plan. These awards, consisting of 842 stock options and 8,296 restricted stock units, were issued at an exercise price of $430.36 per share. The grants were made to incentivize new hires and will vest over several years, helping to retain employees, though they may dilute existing shareholders over time.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced the grant of equity inducement awards to 23 new non-executive employees under its 2025 Inducement Plan. These awards, approved by the independent Compensation Committee, consist of options to purchase 842 shares of common stock and 8,296 time-based restricted stock units. The grants were made on November 1 and November 14, 2026, as an inducement for accepting employment with the company.
MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is investigating Madrigal Pharmaceuticals, Inc. for potential federal securities law violations after the company disclosed a whistleblower complaint. The complaint alleges that Madrigal suppressed adverse liver-injury data and presented unreproducible efficacy data for its drug, Rezdiffra. Following this news, Madrigal's stock price dropped over 8%, and investors who experienced losses are encouraged to contact the law firm.
A fund manager and its investment chief report the same 312,817 Madrigal (MDGL) shares.
RTW Investments, LP and its Managing Partner and Chief Investment Officer, Roderick Wong, have reported shared beneficial ownership of 312,817 shares of Madrigal Pharmaceuticals, Inc. (MDGL) common stock, representing 1.4% of the class. These shares are directly held by certain RTW Funds, with both reporting persons exercising shared voting and dispositive power. The filing was an amended passive investment disclosure (SCHEDULE 13G/A).
What Madrigal Pharmaceuticals Investors Missed Before The Fall
Madrigal Pharmaceuticals experienced a 22.8% loss over the past year despite its drug Rezdiffra clearing US$1.1 billion in net sales. The company successfully transitioned from a quarterly loss of US$114.19 million in Q3 2025 to a US$55.442 million profit in Q3 2026, driven by increased revenue. Current investor sentiment questions whether the recent pullback is a buying opportunity or a warning due to single-drug reliance and future pricing pressures, despite strong patent protection for Rezdiffra.
MDGL Investigation Notification: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) following a whistleblower complaint. The complaint, filed by a former Senior Vice President, alleges Madrigal suppressed adverse liver-injury data and presented unreconcilable efficacy results for its drug, Rezdiffra. Following this disclosure, Madrigal's stock price dropped over 8%, and investors who experienced losses are encouraged to contact the law firm.
Madrigal Pharmaceuticals (MDGL) Stock May Trade At A Discount As Whistleblower Claims Surface
Madrigal Pharmaceuticals' stock, despite strong long-term returns and its liver drug Rezdiffra crossing a US$1 billion sales milestone, may be trading at a discount due to recent whistleblower allegations. The article examines the company's valuation using the P/S ratio and Fair Ratio framework, suggesting that the current share price around US$425 might be below what models imply, possibly reflecting commercial and compliance risks from the investigations. Analysts' consensus also indicates the stock is significantly undervalued, forecasting strong growth and long-term patent protection for Rezdiffra.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in fireside chats at three upcoming investor conferences: the Jefferies Global Healthcare Conference, the Evercore Healthcare Conference, and the Piper Sandler Healthcare Conference. The company will discuss its focus on novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), including its approved medication, Rezdiffra. Webcasts of the fireside chats will be available on Madrigal’s Investor Relations Events page.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in three upcoming investor conferences, beginning November 17, 2026. The company will hold fireside chats at the Jefferies Global Healthcare Conference in London, the Evercore Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. Live webcasts of these events will be available via Madrigal’s Investor Relations Events page.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in fireside chats at three upcoming investor conferences: the Jefferies Global Healthcare Conference, the 9th Annual Evercore Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. The company will discuss its focus on novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), specifically its FDA and European Commission approved medication, Rezdiffra. Webcasts of these events will be available on Madrigal's Investor Relations Events page.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in fireside chats at three upcoming investor conferences: the Jefferies Global Healthcare Conference, the Evercore Healthcare Conference, and the Piper Sandler Healthcare Conference. These webcasts will be accessible live on Madrigal’s Investor Relations Events page. The company will discuss its focus on novel therapeutics for MASH, including its FDA and European Commission approved medication, Rezdiffra.
Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Ongoing Investigation Into Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) for potential securities law violations. This investigation follows a former employee's lawsuit alleging retaliation under the Sarbanes-Oxley Act, claiming the company retaliated after the employee raised concerns about data and reporting practices. The news of the lawsuit led to an 8.08% drop in Madrigal's stock price on November 3, 2026.
Whistleblower Probe Could Be A Game Changer For Madrigal Stock (MDGL)
Madrigal Pharmaceuticals (MDGL) is facing investigations due to a whistleblower complaint alleging issues with Rezdiffra's clinical data integrity, safety reporting, and board oversight. This probe directly impacts Rezdiffra's role as Madrigal's main commercial driver, potentially weakening prescriber confidence and payer terms despite recent positive real-world data. The allegations could cause a significant shift in optimistic financial forecasts for the company.
Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for potential federal securities law violations after a whistleblower complaint alleged the company suppressed adverse liver-injury data and presented unreproducible efficacy data for its drug, Rezdiffra. Following this disclosure in a quarterly report, Madrigal's stock price fell over 8%. Investors who experienced losses are encouraged to contact the law firm to discuss their legal rights.
Madrigal Pharmaceuticals, Inc. (MDGL) Latest Stock News & Headlines - Yahoo Finance
This page provides the latest news and headlines for Madrigal Pharmaceuticals, Inc. (MDGL), including financial updates, analyst ratings, and performance data. Recent articles discuss the company's first profitable quarter, new real-world data for Rezdiffra, and its Q3 2026 earnings. The stock's performance data shows YTD and 1-year declines, but a significant 3-year gain.
Law firm investigates Madrigal Pharmaceuticals over whistleblower retaliation claims, stock drops 8%.
Kaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals following a whistleblower retaliation lawsuit. A former employee claims they raised concerns about company data before resigning, which Madrigal denies. Following the news, Madrigal's stock dropped over 8%.
MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop
Kirby McInerney LLP is investigating Madrigal Pharmaceuticals (MDGL) for potential securities law violations after the stock dropped 8.1% following the disclosure of a whistleblower complaint. The complaint, filed by a former senior executive, alleges suppressed liver-injury data and irreconcilable efficacy results for the company's drug Rezdiffra. No lawsuit has been filed yet, and the firm is evaluating whether claims can be brought under federal securities laws.
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
Hagens Berman, a national securities litigation law firm, has launched an investigation into Madrigal Pharmaceuticals (NASDAQ: MDGL) concerning whistleblower allegations of clinical data integrity and regulatory compliance issues related to its drug Rezdiffra (resmetirom). The investigation follows a complaint by a former Senior VP alleging suppression of adverse liver-injury data, discrepancies in efficacy results, and improper board oversight. Madrigal's stock price fell over 8% after these revelations, and Hagens Berman is encouraging investors with significant losses to come forward.
Is Madrigal Pharmaceuticals (MDGL) Cheap Following Rezdiffra Data And A Swing To Net Income?
Madrigal Pharmaceuticals (MDGL) is back in focus after releasing real-world data for its MASH drug Rezdiffra and reporting a swing to third-quarter net income. Despite a recent single-day share price bounce, the stock is down 27.1% year-to-date, though it has seen significant long-term gains. Analysts at Simply Wall St believe the company is 36.9% undervalued, with a fair value of $686.06, supported by Rezdiffra's rapid uptake, long-term patent protection, and the large addressable MASH patient population.
Madrigal Turns Profitable as Rezdiffra Sales Surge 50%
Madrigal Pharmaceuticals Inc. reported its first profitable quarter, with net income of $55.4 million, driven by a 50% surge in sales of its liver disease treatment, Rezdiffra, to $431.3 million in Q3 2026. Rezdiffra's sales have already surpassed $1.1 billion year-to-date, reaching blockbuster status. The company is expanding its commercial operations and advancing clinical trials to extend Rezdiffra's use for more advanced stages of liver disease.
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
Hagens Berman, a national securities litigation law firm, has launched an investigation into Madrigal Pharmaceuticals (NASDAQ: MDGL) concerning alleged misrepresentation of clinical safety data for its drug Rezdiffra (resmetirom). This inquiry follows a whistleblower complaint filed by a former Senior Vice President, Dr. Michael Charlton, alleging suppression of adverse liver-injury data, discrepancies in efficacy results, and improper board oversight during clinical outcomes adjudication. Following these revelations, Madrigal's stock price dropped by over 8%.
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
This article highlights four commercial-stage biotechnology companies—TG Therapeutics (TGTX), BioCryst Pharmaceuticals (BCRX), Insmed (INSM), and Madrigal Pharmaceuticals (MDGL)—that are well-positioned for sustained revenue growth. Each company has established marketed therapies addressing significant unmet medical needs and is actively expanding its commercial reach through increased adoption, patient access, and potential new indications or formulations. Their recent financial performance and strategic initiatives indicate strong commercial momentum and future growth potential in the competitive biotech market.
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Madrigal Pharmaceuticals, Inc. (MDGL) following allegations of securities law violations. The probe stems from a whistleblower complaint by a former Senior Vice President, Dr. Michael Charlton, who claims Madrigal suppressed adverse liver-injury data and presented unreproducible efficacy results for its Rezdiffra product. Madrigal's shares dropped 8.1% on November 3, 2026, after these allegations surfaced.
What Does Madrigal Pharmaceuticals (MDGL) Whistleblower Probe Mean For Investors?
Madrigal Pharmaceuticals is facing a whistleblower investigation into alleged federal securities law violations concerning liver safety data for its drug Rezdiffra. The complaint suggests the company suppressed adverse liver-injury findings and used unreproducible efficacy results. Investors should monitor official updates, regulatory correspondence, and future disclosures regarding liver injury signals and MASH studies, as the probe challenges the narrative of Rezdiffra as a long-term revenue engine.
Madrigal Pharmaceuticals general counsel Kelley sells $430,800 stock
Madrigal Pharmaceuticals' General Counsel, Kelley Shannon T, sold 1,077 shares of the company's common stock for a total of $430,800 on November 6, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while the stock was trading significantly below its 52-week high, despite the company's strong recent third-quarter performance, which saw it achieve its first profitable quarter and exceed analyst expectations for earnings and revenue.
Form 4 Madrigal Pharmaceuticals Inc: Shannon T. Kelley (General Counsel) For: 6 November By Investing.com
This article reports on a Form 4 filing for Madrigal Pharmaceuticals Inc., indicating a transaction by Shannon T. Kelley, the General Counsel, on November 6th. The filing is available through Investing.com.
Madrigal Pharmaceuticals general counsel Kelley sells $430,800 stock By Investing.com
Madrigal Pharmaceuticals' General Counsel, Shannon T. Kelley, sold 1,077 shares of company stock for $430,800 on November 6, 2026, as part of a pre-arranged trading plan. This sale occurred while the stock was trading significantly below its 52-week high, though InvestingPro analysis suggests it is currently undervalued. The company recently reported its first profitable quarter, exceeding analyst expectations with strong third-quarter 2026 results.
Form 4 Madrigal Pharmaceuticals Inc: BAKER BROS. ADVISORS LP (Director) For: 4 November
This article reports on a Form 4 filing for Madrigal Pharmaceuticals Inc., indicating insider activity by BAKER BROS. ADVISORS LP, a director. The filing pertains to transactions that occurred on November 4th. The article is brief and primarily serves as an announcement of the SEC filing.
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for potential federal securities law violations. This follows a whistleblower complaint alleging that Madrigal suppressed adverse liver-injury data and presented unreproducible efficacy data for its drug, Rezdiffra. The company's stock price dropped over 8% after this disclosure, prompting the law firm to encourage affected investors to contact them regarding their legal rights.
Former Madrigal executive alleges he was forced out after raising concerns about Rezdiffra safety data
A former senior executive at Madrigal Pharmaceuticals has filed a federal lawsuit alleging he was forced out after raising concerns about liver-injury data related to Rezdiffra, the first FDA-approved drug for MASH. Michael Charlton, who led clinical development, claims company leaders censored serious liver-injury data and retaliated against him. Madrigal denies the accusations and defends the drug's safety, with no regulatory action having been announced to date.
Madrigal’s MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales
Madrigal Pharmaceuticals reported encouraging real-world data for its MASH drug, Rezdiffra, showing significant improvements in liver stiffness across four studies, with 37% to 55% of patients experiencing at least a 25% reduction after one year. This positive news follows a whistleblower complaint filed by a former executive regarding data practices, which Madrigal disputes. The company recently achieved its first profitable quarter, with Rezdiffra sales exceeding $1.1 billion year-to-date, leading to raised price targets from analysts.
MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL
Kirby McInerney LLP is investigating potential claims against Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) after a whistleblower complaint revealed allegations of suppressed adverse liver-injury data and unreproducible efficacy data for its drug, Rezdiffra. The complaint, filed by former Senior Vice President Dr. Michael Charlton, alleges that Madrigal's senior executives were aware of these issues and took action against him when he raised concerns. Following this news, Madrigal's shares declined by over 8%.
Madrigal Pharmaceuticals (MDGL) Stock May Be Below Fair Value Despite First Profit
Madrigal Pharmaceuticals (MDGL) has achieved profitability and its liver drug Rezdiffra has surpassed US$1 billion in annual sales, yet its stock price has been under pressure. The company's Price-to-Sales (P/S) ratio of 6.4x is below the biotech industry average and peer group, suggesting it may be undervalued despite its strong sales growth and recent profitability. Investors may still be exercising caution regarding the long-term sustainability of Rezdiffra's revenues in the developing MASH treatment market.
Truist Securities maintains Madrigal Pharmaceuticals at Buy, raises price target to $743 from $709
Truist Securities has reiterated its "Buy" rating for Madrigal Pharmaceuticals and increased its price target to $743 from $709, representing a 4.8% raise. This new target suggests an 87.5% upside from the stock's closing price of $396.32 on November 3. Investors can find more detailed analyst data and recommendations for Madrigal Pharmaceuticals on TradingView's Forecasts tab and News Flow.
Madrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety cover-up
Madrigal Pharmaceuticals is facing a whistleblower lawsuit filed by its former SVP and head of clinical development, Michael Charlton, M.D. The lawsuit alleges that Madrigal's senior leadership covered up serious liver-injury data related to Rezdiffra, the first approved treatment for MASH, and retaliated against Charlton for raising concerns. The complaint also questions data integrity and the role of a co-founder in assessing clinical trial data, leading to a drop in Madrigal's stock price.
Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript
Madrigal Pharmaceuticals reported robust financial results for Q3 2026, with net sales reaching $431 million, a 50% year-over-year increase, pushing year-to-date sales past $1 billion. Their MASH therapy, Rezdiffra, is experiencing rapid growth, nearly doubling its active patient base to over 55,850. The company also announced plans to advance its F4C program with new Phase 3 trials, aiming to be the first approved therapy in that space, and achieved its first profitable quarter with a net income of $55.4 million, demonstrating confidence in Rezdiffra's "mega-blockbuster" potential.
Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop
Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Madrigal Pharmaceuticals, Inc. following an 8.1% drop in its stock price on November 3, 2026. This decline occurred after the company disclosed a whistleblower complaint alleging suppression of adverse liver-injury data and unreconciled efficacy results. The law firm is seeking to determine if Madrigal violated federal securities laws and is inviting investors who suffered losses to contact them regarding potential claims.
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call
Madrigal Pharmaceuticals reported strong Q3 2026 results, with net sales of Rezdiffra up 50% year-over-year, leading to the company's first profitable quarter. The company is expanding its commercial reach, particularly to endocrinologists, and advancing its development program for F4c MASH, with MAESTRO-NASH OUTCOMES study results expected in late 2027. Madrigal also plans to initiate new Phase II combination trials in 2027 and reported significant cash reserves.
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for potential securities law violations following a significant stock price drop. The investigation stems from a former employee's lawsuit alleging retaliation under the Sarbanes-Oxley Act, claiming the company engaged in improper data and reporting practices. Following the disclosure of this lawsuit, Madrigal's stock fell by over 8%.
Madrigal’s Rezdiffra storms past blockbuster milestone as CEO hails ‘accelerating’ MASH market
Madrigal Pharmaceuticals' MASH drug, Rezdiffra, has surpassed $1.1 billion in sales year-to-date, crossing the blockbuster milestone. CEO Bill Sibold highlighted the accelerating MASH market, which is expected to grow over 30% this year, and noted that Rezdiffra has only penetrated about 10% of the current addressable market. The company also plans a new phase 3 trial, Maestro-CSPH, targeting the significant unmet need in patients with clinically significant portal hypertension.
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals announced strong third-quarter 2026 financial results, with Rezdiffra net sales reaching $431.3 million, marking a 50% year-over-year increase and achieving profitability for the first time. Rezdiffra has surpassed blockbuster status with $1.1 billion in year-to-date sales and is showing rapid prescriber adoption, with over 55,850 patients on the drug. The company is also expanding its focus to well-compensated MASH cirrhosis (F4c) with new clinical trials to strengthen its leadership in the MASH market.
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong third-quarter 2026 financial results, with Rezdiffra net sales reaching $431.3 million and achieving profitability for the first time. The company's MASH drug, Rezdiffra, has surpassed $1 billion in year-to-date net sales, achieving blockbuster status. Madrigal is also expanding its clinical trials for MASH cirrhosis and strengthening its leadership in the rapidly growing MASH market.
Madrigal Expands Rezdiffra Evidence With 12,000-Patient Study
Madrigal Pharmaceuticals will present new real-world evidence for its liver disease treatment, Rezdiffra, at a medical conference in Denver, featuring data from over 12,000 patients. This research aims to support the drug's use in routine care and demonstrate its effectiveness, tolerability, and adherence outside of controlled trials, building on the success of its Phase 3 MAESTRO-NASH trial. Rezdiffra is the first medication approved for metabolic dysfunction-associated steatohepatitis (MASH) in the US and Europe.
Madrigal Pharmaceuticals (MDGL) Stock Looks Undervalued On Current Sales Expectations
Madrigal Pharmaceuticals (MDGL) has seen significant gains over five years, but its recent 2026 pullback prompts a review of its current valuation against sales expectations. The stock's current P/S ratio of 7.8x is below the biotech industry average and its peer group, screening as undervalued when adjusted for growth and risks. Upcoming data on Rezdiffra at The Liver Meeting 2026 is anticipated to support long-term sales potential in MASH, which could further justify its valuation.
Madrigal Pharmaceuticals stock trades at 384.25 euros Friday
Madrigal Pharmaceuticals stock traded at 384.25 euros on Friday, October 30, with its next scheduled event on November 3, when the company plans to release its third-quarter 2026 results. The biopharmaceutical company is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), with its first therapy having received accelerated FDA approval. Investors await the upcoming report for updates on operating performance and the MASH business.
Madrigal Pharmaceuticals, Inc. (MDGL) Seasonal Returns Chart - Yahoo Finance
The article displays the seasonal returns chart for Madrigal Pharmaceuticals, Inc. (MDGL) on Yahoo Finance. It shows the average monthly price return for the stock from 2016 to 2026, allowing users to view data for different periods like 3Y, 5Y, 10Y, 20Y, or all available years. The page also provides current stock performance and navigation to other financial data sections.